Stellus Rx, a technology‑enabled pharmacy care‑management platform based in Plano, Texas, has just bought Tria Health, a Kansas City pharmacist‑led chronic‑condition support provider. The deal, backed by WindRose Health Investors, will keep both firms operating under their own names for the near term.

Tria Health specializes in supporting self‑insured employers and their members, helping manage chronic conditions through pharmacist‑led interventions. Stellus Rx’s platform already aggregates prescription data, leverages analytics, and delivers coordinated care. Combining the two gives the buyer a broader portfolio to serve a growing segment of employers seeking cost‑effective health solutions.

Both companies will retain their existing leadership teams and brand identities, allowing Tria’s CEO Jessica Lea to continue steering its operations. The acquisition signals WindRose’s confidence in a hybrid model that blends pharmacy technology with on‑the‑ground pharmacist support, a strategy that could attract more self‑insured clients looking for integrated care in the upcoming years now.

By adding Tria Health, Stellus Rx expands its footprint in the self‑insured market and enhances its value proposition to employers seeking seamless medication management. The move also positions the company to capitalize on rising demand for integrated pharmacy services, potentially boosting revenue streams and market share in a competitive health‑tech arena for 2024 and growth.